 | • レポートコード：MRC2103C142 • 出版社/出版日：Mordor Intelligence / 2021年2月27日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料では、世界の免疫沈降検査市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（単一タンパク質免疫沈降、共免疫沈降（Co-IP）、泌クロマチン免疫沈降（ChIP）、RNA免疫沈降（RIP）、その他）分析、エンドユーザー別（製薬・バイオテクノロジー産業、委託研究機関（CRO）、学術研究所）分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の免疫沈降検査市場規模：種類別（単一タンパク質免疫沈降、共免疫沈降（Co-IP）、泌クロマチン免疫沈降（ChIP）、RNA免疫沈降（RIP）、その他） ・世界の免疫沈降検査市場規模：エンドユーザー別（製薬・バイオテクノロジー産業、委託研究機関（CRO）、学術研究所） ・世界の免疫沈降検査市場規模：地域別 ・競争状況 ・市場機会/将来の見通し |
The Immunoprecipitation Testing market is valued at approximately USD 620 million in 2020 and is expected to witness a revenue of USD 835 million in 2026, with a CAGR of 4.6%, over the forecast period (2021-2026).
The COVID-19 pandemic is expected to have a positive impact on the growth of the studied market. The coronavirus enters the cell when viral spike protein binds to the ACE2 protein, present on the surface of human cells. The immunity among the COVID-19 recovered patients is predicted to be developed as a result of the presence of neutralizing antibodies that block this binding. Hence, researchers are involved in studying the protein interactions and action of neutralizing antibodies. For instance, as per the research study published in Science Daily, 2020, researchers applied immunoprecipitation associated with flow cytometry(IP-FCM) in studying the interactions of proteins in SARS-CoV2 infection and the role of antibodies in blocking the virus from binding to cells. Thus, given the ongoing pandemic and increasing research activities, the studied market is expected to be significantly impacted by the current crisis.
The immunoprecipitation testing market is found increasing due to the rise in the prevalence of autoimmune disorders which requires antibody-antigen interaction testing. Additionally, the growing opportunities of funding and investments from the government and non-government organizations towards the research on next-generation DNA sequencing and genomics are fuelling the market growth. In Feb 2021, the National Institute of Allergy and Infectious Diseases (NIAID), initiated a Phase 1 clinical study to evaluate the safety and immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine, in which the secondary immunogenicity endpoints are measured using luciferase immunoprecipitation assay. Along with that, the growing applications of immunoprecipitation testing in central nervous disorders, cancers, and cardiovascular diseases are also boosting the growth of the immunoprecipitation testing market. The tumor cells that are resistant to drugs exhibit dynamic protein-prorein interactions and immunoprecipitation testing aids in studying these interactions among cancer patients. According to the Globocan 2020 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths due to cancers globally. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. Thus, the growing burden of cancers is also expected to drive market growth.
For instance, in 2019, Merck & Co. Inc. established a new life science facility the is majorly aimed at research and development activities related to the areas of oncology, immunology, and immuno-oncology. However, limitations in sample size, variations in lipid content might hamper the wide application of this test which is expected to impede the market growth.
Key Market Trends
Chromatin Immunoprecipitation (ChIP) is Expected to Dominate the Market by Type over the Forecast Period
Chromatin Immunoprecipitation (ChIP) is a type of immunoprecipitation technique that is used to investigate the regions of the genome associated with target DNA-binding protein, or on the other hand to identify the specific proteins that are associated with a specific region of the genome. Chromatin Immunoprecipitation is commonly used in epigenetics research.
ChIP is expected to experience significant growth owing to technological advances. For instance, Chromatrap technology enables the accuracy of data and delivers quick results without any pipetting risks which allow researchers to simultaneously analyze multiple antibodies and gene targets.
In the current COVID-19 pandemic, ChIP plays a vital role in determining the protein-DNA interactions, which is very important in understanding the target binding sequences for the SARS-Cov2 Virus. Thus, as the research progresses in this direction, the studied segment is expected to witness significant growth during the pandemic era.
Additionally, the key players are involved in research activities for the development of improved protocols for chromatin immunoprecipitation which aids in the growth of the studied market. For instance, in the study published in Bio-Protocol, 2020, chromatin immunoprecipitation coupled with quantitative PCR (Chip-qPCR), was used in the identification of binding sites of DNA binding proteins and the detection of histone modification on a locus-specific areas of the genome. Hence, the extensive application of ChIP in various genomic studies acts as a major factor driving the studied segment over the forecast period.
North America Holds the Major Share in Immunoprecipitation Testing Market and is Expected to Dominate the Market Over the Forecast Period
North America holds the major share in the immunoprecipitation testing market owing to the increasing investments and funding from the governments especially in biotechnology research, and growing awareness regarding personalized medicine. Additionally, growing collaborations and partnerships between organizations and universities, along with a high concentration of key players in the region are expected to drive the studied market in the region. Various government bodies, like NHGRI (National Human Genome Research Institute), have supported the work on sequencing of the human genome and funded the research the involves the study on the genome’s structure, function, and role in human health and various disease.
With the growing number of COVID-19 cases in the region, particularly in the United States, extensive research is being carried out employing advanced tools such as immunoprecipitation sequencing in studying the DNA-protein interactions and genome analysis. Additionally, according to the research article published by the National Institutes of Health(NIH), 2020, the prevalence of antinuclear antibodies (ANA), which is the common biomarker of autoimmunity, was significantly increasing in the United States over the years. Thus, given the aforementioned factors, the North American region is expected to witness significant growth over the forecast period.
Competitive Landscape
The immunoprecipitation Testing market has rapidly evolved over the last few years. The major players for the studied market are expanding the product portfolio through strategies such as product developments, mergers, and acquisitions in recent years. Thus, the Immunoprecipitation Testing market has become a moderately competitive industry. The major players in the studied market include Merck KGaA, Thermo Fisher Scientific, Inc., Bio-rad laboratories, GenScript Biotech Corporation, Biologics International Corp among others.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definnition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Research and Development Activities in Life-sciences
4.2.2 Increasing Need to Identify Antigens Associated With Autoimmune Diseases
4.3 Market Restraints
4.3.1 Availability of Alternative Techniques
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Individual protein immunoprecipitation
5.1.2 Co-Immunoprecipitation (Co-IP)
5.1.3 Chromatin Immunoprecipitation (ChIP)
5.1.4 RNA Immunoprecipitation (RIP)
5.1.5 Others
5.2 By End User
5.2.1 Pharmaceutical and Biotechnology Industries
5.2.2 Contract Research Organizations (CRO’s)
5.2.3 Academic & Research Institutes
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific Inc.
6.1.2 Abcam Plc
6.1.3 Bio-Rad Laboratories
6.1.4 Biologics International Corp
6.1.5 Creative Proteomics
6.1.6 GenScript Biotech Corporation
6.1.7 Merck KGaA
6.1.8 Novus Biologicals
6.1.9 Takara Bio Inc.
6.1.10 Rockland Immunochemicals, Inc.
6.1.11 Cell Signalling Technology, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS